A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma

A Prospective Non-Interventional Study in Participants Receiving Nivolumab in Adjuvant Setting for Resected Melanoma in Real-World Conditions in France

NCT04550247 ·Status: ACTIVE_NOT_RECRUITING

Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic

NCT02094872 ·Status: COMPLETED ·Phase: PHASE2

Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma

NCT02107755 ·Status: COMPLETED ·Phase: PHASE2

RTA 408 Capsules in Patients With Melanoma - REVEAL

NCT02259231 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Treatment Patterns and Outcomes Study in Patients With Unresectable Stage III and Metastatic (Stage IV) Melanoma in the United States

NCT03199846 ·Status: COMPLETED

Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma

NCT00324155 ·Status: COMPLETED ·Phase: PHASE3

Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma

NCT01709162 ·Status: TERMINATED ·Phase: PHASE2

Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma

NCT02141542 ·Status: COMPLETED ·Phase: PHASE1

SB-715992 in Treating Patients With Metastatic or Recurrent Malignant Melanoma

NCT00095953 ·Status: COMPLETED ·Phase: PHASE2

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

NCT01511913 ·Status: COMPLETED

Ipilimumab With Carboplatin and Paclitaxel in Patients With Unresectable Stage III and Stage IV Melanoma

NCT01676649 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma

NCT01213472 ·Status: COMPLETED ·Phase: PHASE1

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

NCT01515189 ·Status: COMPLETED ·Phase: PHASE3

Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma

NCT01681212 ·Status: COMPLETED ·Phase: PHASE2

Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

NCT01134614 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

NCT01708941 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma

NCT02306850 ·Status: COMPLETED ·Phase: PHASE2

PS-341 in Treating Patients With Metastatic Malignant Melanoma

NCT00024011 ·Status: COMPLETED ·Phase: PHASE2

A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)

NCT02156804 ·Status: COMPLETED ·Phase: PHASE2

A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma

NCT01654692 ·Status: COMPLETED ·Phase: PHASE2

A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma

NCT04007588 ·Status: WITHDRAWN ·Phase: PHASE2

Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases

NCT04812470 ·Status: COMPLETED ·Phase: PHASE1

A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors

NCT03052205 ·Status: COMPLETED ·Phase: PHASE1

Efficacy Study of TLN-232 in Patients With Recurring Metastatic Melanoma

NCT00735332 ·Status: TERMINATED ·Phase: PHASE2

AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma

NCT00243061 ·Status: COMPLETED ·Phase: PHASE2